

# This Week's **Top** Industry News

Provided as a service to DCAT member companies each Friday.

**BUSY WEEK?** Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director **Patricia Van Arnum**.

Sponsored By:



Spectrum Offers 1200+ USP/NF cGMP Products.  
Order Your 2016 USP Catalog!



[Click Here](#)

## 1. [EC Okays Teva's \\$40.5 Billion Acquisition of Allergan's Generics Business](#)

Teva Pharmaceutical Industries has received regulatory approval from the European Commission for its \$40.5 billion acquisition of Allergan plc's global generics business, subject to certain divestments. Teva is still working with the US Federal Trade Commission to gain regulatory approval in the US. [Read More](#)

## 2. [Teva Completes \\$2.3 Billion Acquisition of Risma](#)

Teva Pharmaceutical Industries has completed its previously announced \$2.3 billion acquisition of Representaciones e Investigaciones Médicas, S.A. de C.V. (Rimsa), a pharmaceutical manufacturing and distribution company in Mexico. [Read More](#)

## 3. [Merck & Co. Names New Head of Manufacturing](#)

Merck & Co. has appointed Sanat Chattopadhyay as executive vice president and president, Merck Manufacturing Division (MMD), effective April 1, 2016. Chattopadhyay will succeed Willie A. Deese who will retire on June 1, 2016 after 12 years with the company. [Read More](#)

## 4. [Sanofi, Merck End European Vaccines Joint Venture](#)

Sanofi and Merck & Co. Inc. have announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their product portfolios, and pursue their own distinct growth strategies in Europe. [Read More](#)

## 5. [Lupin Completes Acquisition of GAVIS](#)

Lupin Limited, a Mumbai, India-headquartered pharmaceutical company, has completed its previously announced acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. The move gives Lupin its first US-based manufacturing facility. [Read More](#)

## 6. [Swissmedic Reports Counterfeit Harvoni Found in Israel](#)

The Swiss Agency for Therapeutic Products (Swissmedic) reports that counterfeit packs of the preparation of Gilead Sciences' hepatitis C drug, Harvoni (ledipasvir/sofosbuvir), have been discovered in Israel. The plastic bottles, which originated in India, were imported via a Swiss trading company. Harvoni was Gilead's top-selling drug in 2015 with sales of \$13.9 billion. [Read More](#)

## 7. [AbbVie, BI Partner on Immunology Compounds](#)

AbbVie and Boehringer Ingelheim have formed a global collaboration to develop and commercialize a monoclonal biologic antibody in Phase III development for psoriasis and have partnered for an anti-CD-40 antibody in Phase I development. Under the the license agreement, AbbVie will make an initial upfront payment of \$595 million. [Read More](#)

#### **8. [Dr. Reddy's Signs Biosimilars Pact in Turkey](#)**

Dr. Reddy's Laboratories has formed a strategic partnership with TR-Pharm, an Istanbul, Turkey-based pharmaceutical company, involving three biosimilar products. TR-Pharm will manufacture the drug substance and drug product upon completion of its facility investment. [Read More](#)

#### **9. [Hovione, Vertex Pharmaceuticals Partner for Continuous Manufacturing](#)**

Hovione has announced plans to host and operate a commercial-scale continuous manufacturing facility as part of an agreement with Vertex Pharmaceuticals. The facility will be installed in Hovione's New Jersey location and is expected to be completed by the end of 2017. [Read More](#)

#### **10. [DPT, Confab Complete \\$10 Million Capital Investment](#)**

DPT Laboratories, a contract development and manufacturing organization specializing in semi-solid and liquid dosage forms, and Confab, a DPT company specializing in complex solids, semi-solids and liquids, have completed a combined \$10 million capital investment. [Read More](#)

**\*New to DCAT Week '16\***

#### **[Get the Latest News from Senior Executives at DCAT Week '16](#)**

What are the major company developments impacting the pharmaceutical manufacturing value chain? DCAT's Member Company Announcement Forum kicks off DCAT Week '16 with the latest news and insight from senior executives. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!*

---

#### **[About Top Industry News](#)**

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ [esanders@dcat.org](mailto:esanders@dcat.org)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)